Venadaparib (example 143; 6-10 days) shows potent growth inhibition of MDA-MB-436 cells and Capan-1 pancreatic cancer cells with IC 50 values of ≤5nM and 50nM[2].

In the germline BRCA1-mutated ovarian cancer PDX model, oral administration of Venadaparib (IDX-1197) exhibits significant PAR inhibition (>90%) in tumor tissues until 24 hr post dose. Venadaparib also dose-dependently led to potent tumor growth inhibition compared to Olaparib treatment group[1].